Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  idarubicin hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 60 for your search:
Start Over
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 55
Sponsor: Other
Protocol IDs: GMALL02, NCT00198978
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991
Efficacy of G-CSF-Priming in Elderly AML Patients
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: MK1-192, NCT00180128
Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 55 and over
Sponsor: Other
Protocol IDs: LAL-07OLD, NCT01366898
Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: LAL-AR/2011, NCT01540812
HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: HIE-ALL-2013, NCT01873807
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: APL2012, NCT01987297
Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 6 months to 18 years
Sponsor: Other
Protocol IDs: CCALL2012, NCT01990807
Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: CWS-2007-HR, 4033024 (BfArM), 293/2007AMG1 (Ethikkommission), 2007-001478-10, A2007/14 (Kinderkrebsstiftung), 498 (Krebsstudienregister), NCT00876031
Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: C-022, NCT01145846
Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: AML 2002 #061, NCT01414231
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 7 to 60
Sponsor: Other
Protocol IDs: MST-AML-307PLAH-ASH, NCT01484171
the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 50
Sponsor: Other
Protocol IDs: GuangXi-AML- HSCT-2012-07, NCT01766375
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 to 60
Sponsor: NCI
Protocol IDs: NCI-2013-00490, PS1203_A06PAMDREVW01, SWOG-S1203, S1203, U10CA180888, U10CA032102, NCT01802333
"InDACtion" vs "3+7" Induction in AML
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: EORTC-1301, 2014-001486-27, NCT02172872
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Approved-not yet active
Age: 60 and over
Sponsor: Other
Protocol IDs: AML18, NCT02272478
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 to 60
Sponsor: Other
Protocol IDs: SZ3202, NCT02323022
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 12 to 21
Sponsor: NCI, Other
Protocol IDs: AAML1331, NCI-2014-02266, U10CA180886, NCT02339740
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Phase: Phase III
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2215-CL-0301, 2015-000140-42, NCT02421939
Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: EORTC-06061, EU-20905, 2006-004912-28, GIMEMA-AML-14A, EudraCT-2006-004912-28, NCT00838240
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0788, NCI-2011-00251, NCT01289457
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: PLERIFLAG, NCT01435343
Start Over